Literature DB >> 4027473

Histamine is an antagonist of the acetylcholine receptor at the frog endplate.

M Ariyoshi, H Hasuo, K Koketsu, Y Ohta, T Tokimasa.   

Abstract

The effects of histamine on the acetylcholine (ACh) receptor-channel complex were examined by means of voltage-clamp at the frog endplate. ACh was ionophoretically applied to the endplate. Histamine was added to the perfusate. Histamine (100 nM - 1 mM) reversibly depressed the peak amplitude of the ACh-induced inward current in a dose-dependent manner. The double reciprocal plot of the dose-response relationship between the peak ACh current and the amount of ACh applied suggested that histamine (100 microM) depressed the ACh-induced current in a competitive manner. Histamine prevented the specific ACh binding site within the receptor-channel complex from binding erabutoxin, a sea-snake venom, which binds irreversibly to the specific ACh binding site. Histamine had no detectable effects on the equilibrium potential of the endplate current but shortened the half-decay time of the endplate current in a voltage-dependent manner. It was therefore concluded that histamine blocks not only the specific ACh binding site but also interacts with the ACh-channel site. The present experiments strongly suggest that histamine can act as an antagonist to modulate nicotinic cholinergic transmission.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4027473      PMCID: PMC1916774          DOI: 10.1111/j.1476-5381.1985.tb08832.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  16 in total

1.  'Glycerol effect' and the mechanism linking excitation of the plasma membrane with contraction.

Authors:  M FUJINO; T YAMAGUCHI; K SUZUKI
Journal:  Nature       Date:  1961-12-23       Impact factor: 49.962

2.  Effects of elabutoxins on neuromuscular transmission in frog skeletal muscles.

Authors:  E Kato; K Kuba; K Koketsu
Journal:  J Pharmacol Exp Ther       Date:  1978-02       Impact factor: 4.030

3.  A re-examination of curare action at the motor endplate.

Authors:  B Katz; R Miledi
Journal:  Proc R Soc Lond B Biol Sci       Date:  1978-12-04

4.  Analysis of the effects of histamine on the end-plate potential.

Authors:  M Scuka
Journal:  Neuropharmacology       Date:  1973-05       Impact factor: 5.250

5.  The effect of voltage on the time course of end-plate currents.

Authors:  K L Magleby; C F Stevens
Journal:  J Physiol       Date:  1972-05       Impact factor: 5.182

6.  Determination of dose-response curves by quantitative ionophoresis at the frog neuromuscular junction.

Authors:  F Dreyer; K Peper; R Sterz
Journal:  J Physiol       Date:  1978-08       Impact factor: 5.182

7.  Novel action of a piperazine derivative on the end-plate of the frog.

Authors:  K Kuba; K Chikazawa; K Koketsu
Journal:  Jpn J Physiol       Date:  1976

8.  The amino acid sequences of erabutoxins, neurotoxic proteins of sea-snake (Laticauda semifasciata) venom.

Authors:  S Sato; N Tamiya
Journal:  Biochem J       Date:  1971-05       Impact factor: 3.857

9.  Effects of membrane potential, temperature and neostigmine on the conductance change caused by a quantum or acetylcholine at the toad neuromuscular junction.

Authors:  P W Gage; R N McBurney
Journal:  J Physiol       Date:  1975-01       Impact factor: 5.182

10.  Studies on sea-snake venoms. Crystallization of erabutoxins a and b from Laticauda semifasciata venom.

Authors:  N Tamiya; H Arai
Journal:  Biochem J       Date:  1966-06       Impact factor: 3.857

View more
  2 in total

1.  Enhancement by 5-hydroxytryptamine and analogues of desensitization of neuronal and muscle nicotinic receptors expressed in Xenopus oocytes.

Authors:  K M Cross; R C Foreman; J E Chad
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

2.  On the histamine-induced depolarization of the isolated superior cervical ganglion of the rat.

Authors:  J L Field; N R Newberry
Journal:  Br J Pharmacol       Date:  1991-07       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.